- Learning from product labels and label changes: how to build pharmacogenomics into drug-development programsLinda C Surh
Global Regulatory Affairs, GlaxoSmithKline, UK
Pharmacogenomics 11:1637-47. 2010....
- Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'Linda C Surh
CEDD, Global Regulatory Affairs, Neurology and Pharmacogenetics, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, UB6 OHE, UK
Pharmacogenomics 10:137-47. 2009..All converge onto a label that must communicate evidence-based use of a new medicine that is effective and safe...